Upstream Bio stock jumps 8% on Phase 2 severe asthma data (UPB:NASDAQ)
· seekingalpha.com
Upstream Bio (UPB) jumps 8% after Phase 2 VALIANT data for severe asthma drug verekitug.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...